Corpus ID: 53606972

Profile of acylcarnitines, inflammation and oxidative stress in first-episode psychosis before and after antipsychotic treatment

@inproceedings{Kriisa2018ProfileOA,
  title={Profile of acylcarnitines, inflammation and oxidative stress in first-episode psychosis before and after antipsychotic treatment},
  author={K. Kriisa},
  year={2018}
}
8 Citations

References

SHOWING 1-10 OF 472 REFERENCES
Altering the course of schizophrenia: progress and perspectives
TLDR
A broad-based consideration of the challenges and opportunities inherent in efforts to alter the course of schizophrenia is provided, including 'hybrid' strategies that both relieve presenting symptoms and reduce the risk of transition to schizophrenia or another psychiatric disorder. Expand
Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index
TLDR
EGF was the strongest marker of FEP and treatment efficiency among the measured cytokines and growth factors and the suppression of positive symptoms was correlated with the decreased levels of EGF, IL-2 and IL-4. Expand
Meta-Analysis of Oxidative Stress in Schizophrenia
TLDR
Oxidative stress abnormalities in FEP suggest an effect that might be independent of antipsychotic medications, and oxidative stress might serve as a potential biomarker in the etiopathophysiology and clinical course of schizophrenia. Expand
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
TLDR
Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. Expand
A meta-analysis of oxidative stress markers in schizophrenia
TLDR
It was shown that TBARS and NO significantly increased in SCZ, while SOD activity significantly decreased in the disorganized type of SCZ patients, which demonstrated the involvement of oxidative stress in the pathophysiology of schizophrenia. Expand
Increased Levels of Plasma Acylcarnitines in Obesity and Type 2 Diabetes and Identification of a Marker of Glucolipotoxicity
TLDR
This study focused on characterizing AcylCN profiles in human plasma from individuals with obesity and T2DM during fasting and insulin‐stimulated conditions, suggesting that more fatty acids can enter mitochondria. Expand
Immune and metabolic alterations in first episode psychosis (FEP) patients
TLDR
Data evidence a profile of immune and metabolic alterations in FEP patients, providing new information on the molecular mechanism associated to the psychosis onset for the development of preventive strategies and innovative treatment targets. Expand
Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis
TLDR
Results based on individual studies suggest that greater inflammation and oxidative stress might lead to poorer outcomes in patients with first episodes of early onset psychosis. Expand
Cytokine profile in drug-naïve, first episode patients with psychosis.
TLDR
The serum levels of IL-2 and IL-6 are increased in first episode drug-naïve patients with psychosis compared to healthy controls, suggesting that an inflammatory response mediated by IL- 2 andIL-6 may play a role in schizophrenia. Expand
The promise of biological markers for treatment response in first-episode psychosis: a systematic review.
TLDR
A systematic review of trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments are provided. Expand
...
1
2
3
4
5
...